The interim experts’ counsil resolution on the EMPA-REG OUTCOME trial issues
The interdisciplinary interim experts’ counsil on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of prorositions and remommendations on further empagliflozin’s cardiovascular effects investigation and it’s clinical appl...
Enregistré dans:
Auteur principal: | Editorial team Diabetes Mellitus |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/5f7ca36e59854d25a5d206eef64bffb3 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
par: Editorial team Diabetes Mellitus
Publié: (2012) -
DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
par: Marina V. Shestakova
Publié: (2019) -
Expert committee on introduction of incretin-based therapy in Russia: advance and failure
par: Editorial team Diabetes Mellitus
Publié: (2012) -
Russian Association of Endocrinologists reports commencement of Amaril clinical use
par: Editorial team Diabetes Mellitus
Publié: (2012) -
Meeting of the expert committee on the use of pre-mixed insulin preparation Humalog Mix 50 in type 2 diabetes mellitus
par: Editorial team Diabetes Mellitus
Publié: (2013)